Pharmaceuticals News and Research

RSS

Daiichi Sankyo chooses IntraLinks as its information sharing solution

IntraLinks, the leading provider of critical information exchange solutions, announced today that Daiichi Sankyo has selected IntraLinks as the company's information sharing solution.

19 Jan 2010

Top pharmaceutical companies choose Cegedim Dendrite's cMDM solution

Cegedim Dendrite today announced that four prominent Life Sciences companies have contracted for its Customer Master Data Management (cMDM) solution, Nucleus as a Service, within the last four months. Three of the four are among the world’s top-25 pharmaceutical companies and the fourth is a mid-sized specialty pharmaceutical company. Cegedim Dendrite is the leading provider of Customer Relationship Management (CRM), Marketing, Regulatory Compliance and Data Optimization solutions designed specifically for the Life Sciences industry.

19 Jan 2010

Sodium oxybate to garner over 15% of the fibromyalgia drug market despite safety concerns

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite potential safety concerns, Jazz Pharmaceuticals/UCB's sodium oxybate (JZP-6) will account for more than 15 percent of the fibromyalgia drug market in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Sodium oxybate has demonstrated robust efficacy in Phase III clinical trials for fibromyalgia and interviewed thought leaders are impressed with its effect on several key symptom domains of fibromyalgia, which include pain, sleep and fatigue.

18 Jan 2010

AstraZeneca and Dako Denmark A/S enter into collaboration agreement

AstraZeneca and Dako Denmark A/S announced today that they have entered into a collaboration agreement to develop companion diagnostic tests for multiple AstraZeneca oncology projects, including biologics and small molecules, in various stages of discovery and development.

18 Jan 2010

Sunlight and vitamin D deficiency linked to 17 varieties of cancer

For humans, sunlight and vitamin D is critically important for the development, growth, and maintenance of a healthy body, from birth until death. "Humans make thousands of units of vitamin D within minutes of whole body exposure to sunlight. From what we know of nature, it is unlikely such a system evolved by chance," states Dr. John Cannell, Executive Director, Vitamin D Council.

18 Jan 2010

ERT Knowledge Series of educational papers discusses patient safety in clinical trials

ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.

18 Jan 2010

Medical innovation needed despite current economic problems, says Eli Lilly CEO

In the keynote address at a Town Hall Los Angeles luncheon event today, John C. Lechleiter, Ph.D., chairman and CEO of Eli Lilly and Company, said that in the current challenging economic times, sustaining our nation's edge in innovation and improving our focus on medical innovation's richest resource – people – is imperative to achieving prosperity and health in the coming decade. His speech focused on bioscience innovation, a sector in which Los Angeles boasts one of the largest concentrations of jobs in the country.

18 Jan 2010

New report providing insight for companies developing therapies to treat hematologic malignancies published

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing therapies to treat hematologic malignancies.

18 Jan 2010

Sirnaomics certifies polypeptide nanoparticle technology

Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has licensed a polypeptide nanoparticle technology invented by Professor A. James Mixson of University of Maryland Medical School.

18 Jan 2010

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Regulus Therapeutics Inc. today announced that new pre-clinical data from multiple therapeutic programs were presented at the “RNA Silencing: Mechanism, Biology and Application” Keystone Symposium held January 14 – 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing microRNA target regulation by anti-miRs, as well as data from therapeutic programs focused on oncology, immune disease and hepatitis C virus (HCV) infection.

18 Jan 2010

FDA extends Tarceva's sNDA review period

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for Tarceva® (erlotinib) as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) by an additional 90 days.

18 Jan 2010

Obama signals interest in reducing the protections for biologic drugs

Lobbyists for generic biologic drugmakers are fighting to undercut a provision in the proposed health overhaul that would protect brand-name pharmaceutical companies from lower-cost, generic competition over new products for 12 years, the Associated Press reports. The generic companies have friends in high places: "White House officials and Rep. Henry Waxman, D-Calif., chairman of the House Energy and Commerce Committee, are trying to reduce the curbs against competition to 10 years or less" (Fram, 1/14).

18 Jan 2010

Medpace acquires Medical Consulting Dr. Schlichtiger

Medpace, a privately held, global, full-service clinical research organization, is pleased to announce that it has acquired Medical Consulting Dr. Schlichtiger GmbH, a European CRO with extensive drug development expertise providing customized regulatory and pharmacovigilance services to pharmaceutical, biotechnology and nutritional companies of all sizes based in Munich, Germany.

18 Jan 2010

Karolinska Development AB and BioChromix AB form BioChromix Pharma AB

Karolinska Development AB (publ), and BioChromix AB announced today the formation of BioChromix Pharma AB, a new company working to develop a novel Alzheimer treatment with its unique knowledge of molecular chemistry. Karolinska Development will initially take 28 percent ownership in the new company.

18 Jan 2010

EMA PDCO grants specific waivers for Gamida Cell-Teva JV's StemEx study in paediatric patients

The Gamida Cell-Teva Joint Venture (JV) announced today that the Paediatric Committee (PDCO) of the EMA has granted product specific waivers for StemEx for all subsets of the paediatric population (birth to 17 years of age) in all conditions. The PDCO emphasized that the granting of the waivers should not prevent the JV from considering developing StemEx for children with conditions where there is a need. StemEx is being developed by a joint venture equally owned and operated by Gamida Cell and Teva Pharmaceuticals ( TEVA).

18 Jan 2010

Democrats reportedly settle key issues on health bill but no final accord yet

Politico reports: "President Barack Obama and senior Democratic lawmakers closed in Friday on a final health care reform package, finishing a week of intensive negotiations on tax and coverage issues that had once threatened to derail the bill.

18 Jan 2010

Dartmouth researchers to develop and market a drug throughout Asia for treatment of CKD

Thanks in part to more than a decade of preclinical work by Dartmouth researchers, a Japanese biopharmaceutical firm is preparing to develop and market throughout Asia a drug for the treatment of chronic kidney disease (CKD).

18 Jan 2010

Multiple issues still on the table in House-Senate health bill negotiations

Reports explored contentious policies in the House and Senate versions of the health-overhaul legislation that are part of the final negotiations.

18 Jan 2010

H.I.G. Capital acquires Allion Healthcare

H.I.G. Capital, LLC, a leading global private equity firm, today announced that an affiliate has closed its previously announced acquisition of Allion Healthcare, Inc. (NASDAQ: ALLI).

18 Jan 2010

WHO official rejects claims agency overhyped threat of H1N1

Keiji Fukuda, the special adviser to the WHO director general on pandemic influenza, on Thursday dismissed allegations that the agency exaggerated the threat of the H1N1 (swine flu) pandemic and has been influenced by the pharmaceutical industry, the Washington Post reports.

18 Jan 2010